Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
$70.61
Intrinsic $94.15 · 25% MOS
Current price: $78.71
Base-case summary
Our base-case DCF for Zoetis Inc. (ZTS) projects 10 years of free cash flow growth at 5.2% for years 1–5 and 2.6% for years 6–10, anchored to 5.2% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $2.2B in trailing free cash flow, this produces an intrinsic value of $94.15 per share. A 25% safety margin gives a fair value of $70.61, suggesting the stock is currently 10% overvalued against the $78.71 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$2.2B
Cash & equivalents
$1.9B
Total debt
$9.2B
Shares outstanding
422M